Generation Bio Co.GBIOEarnings & Financial Report
Generation Bio Co. is a clinical-stage biotechnology firm focused on developing innovative non-viral gene therapies for both rare and common genetic diseases. Its core pipeline targets liver and retina disease indications, operates primarily in the U.S. market, and aims to deliver potential one-time curative treatments to patients with unmet medical needs.
GBIO Q3 FY2025 Key Financial Metrics
Revenue
$1.6M
Gross Profit
N/A
Operating Profit
$-6.7M
Net Profit
$-5.5M
Gross Margin
N/A
Operating Margin
-420.8%
Net Margin
-346.3%
YoY Growth
-78.9%
EPS
$-0.82
Generation Bio Co. Q3 FY2025 Financial Summary
Generation Bio Co. reported revenue of $1.6M (down 78.9% YoY) for Q3 FY2025, with a net profit of $-5.5M (up 64.0% YoY) (-346.3% margin).
Key Financial Metrics
| Total Revenue | $1.6M |
|---|---|
| Net Profit | $-5.5M |
| Gross Margin | N/A |
| Operating Margin | -420.8% |
| Report Period | Q3 FY2025 |
Generation Bio Co. Annual Revenue by Year
Generation Bio Co. annual revenue history includes year-by-year totals (for example, 2024 revenue was $19.9M).
Generation Bio Co. Quarterly Revenue & Net Profit History
Generation Bio Co. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $1.6M | -78.9% | $-5.5M | -346.3% |
| Q2 FY2025 | $765.0K | -81.3% | $-20.9M | -2735.0% |
| Q1 FY2025 | $8.7M | +114.9% | $-14.8M | -169.7% |
| Q4 FY2024 | $4.2M | +45.5% | $-21.4M | -510.6% |
| Q3 FY2024 | $7.6M | +252.0% | $-15.3M | -202.7% |
| Q2 FY2024 | $4.1M | +364.9% | $-20.4M | -499.4% |
| Q1 FY2024 | $4.1M | — | $-74.5M | -1836.4% |
| Q4 FY2023 | $2.9M | — | $-35.2M | -1222.6% |
Income Statement
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.9M | $4.1M | $4.1M | $7.6M | $4.2M | $8.7M | $765000 | $1.6M |
| YoY Growth | N/A | N/A | 364.9% | 252.0% | 45.5% | 114.9% | -81.3% | -78.9% |
Balance Sheet
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $374.8M | $285.9M | $265.3M | $248.8M | $231.2M | $201.3M | $179.4M | $121.9M |
| Liabilities | $171.6M | $153.9M | $149.9M | $144.3M | $145.0M | $128.0M | $125.3M | $71.3M |
| Equity | $203.1M | $132.0M | $115.4M | $104.4M | $86.2M | $73.3M | $54.1M | $50.6M |
Cash Flow
| Q4 2023 | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-25.0M | $-31.7M | $-21.5M | $-19.5M | $-15.8M | $-28.4M | $-16.8M | $-52.7M |